Dr Ashley Yocum speaks to ecancer about a study presented at ASH 2024 as part of the Beat AML master clinical trial.

She reports that the dataset, the largest for this demographic, includes 1,023 patients from the BDML Master trial. Findings show 9.7% have an IDH1 mutation and 18.9% have an IDH2 mutation.

The study highlights the importance of IDH inhibitors for treatment and their impact on patient outcomes.